1.
Cancer-Related Muscle Loss
Cancer-related muscle loss, or cachexia, is characterized by progressive weight loss and rapid wasting of lean muscle mass. ...
2.
Cancer-Related Muscle Loss
Cancer-related muscle loss, or cachexia, is characterized by progressive weight loss and rapid wasting of lean muscle mass. ...
3.
ACE-011 (Bone Growth)
The growth of new bone stimulated by ACE-011 has the potential to improve ... has the potential to significantly improve the bone health of these patients. ...
4.
Treatment with a Soluble Activin Receptor Type llB Attenuates ...
File Format: PDF/Adobe Acrobat - View as HTML activin type llb receptor (ActRllB) ... administered by ip injection twice/week at 10 mg/kg. ... ACE-031 1.0mg/kg. ACE-031 3mg/kg. ACE-031 10mg/kg ...
5.
Therapeutic Areas
Biotherapeutic technologies for protein therapeutic development.
6.
Acceleron Pharma’s ACE-031 Increases Muscle Mass and Strength in ...
May 14, 2007 ... ACE-031 inhibits negative regulators of muscle to increase muscle mass and strength as a potential treatment for neuromuscular diseases and ...
7.
Acceleron Pharma’s ACE-031 Increases Muscle Mass In a Preclinical ...
Oct 18, 2007 ... In preclinical models, ACE-031 increased skeletal muscle mass and strength in disease models of amyotrophic lateral sclerosis (ALS), ...
8.
Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino ...
Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration. Download PDF. CAMBRIDGE, Mass. ...
9.
Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard ...
Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard of Excellence” by the Web Marketing Association. Download PDF. Cambridge, Mass. ...
10.
Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard ...
Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard of Excellence” by the Web Marketing Association. Download PDF. Cambridge, Mass. ...